Abstract
Recent literature has addressed a common dyad: alcoholism and anxiety. Both disorders have been interdigitated with the brain amine serotonin. We investigated 51 dually diagnosed patients (generalized anxiety/alcohol abuse:dependence) in a randomized, double-blind, placebo-controlled trial of the serotonin partial agonist buspirone. Buspirone was superior to placebo as an anxiolytic, was well tolerated, and was associated with both a reduction in the number of days desiring alcohol and an overall clinical global improvement.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
